Reozalimab

Reozalimab is a bispecific antibody targeting to PD-1/PD-L1. Reozalimab mediates antibody-dependent cell cytotoxicity in cancer research[1][2].

Product Specifications

CAS Number

[2445259-99-2]

Product Name Alternative

LY3434172

UNSPSC

12352203

Target

PD-1/PD-L1

Type

Inhibitory Antibodies

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/reozalimab.html

Purity

99.90

Solubility

10 mM in DMSO|H2O

Smiles

[Reozalimab]

Molecular Weight

(143.55 kDa)

References & Citations

[1]Pattabiraman, et al. Synthetic IL-7 and IL-7-anti-PD-1 antibody immunocytokines for cancer therapy. World Intellectual Property Organization, WO2023281484 A1 2023-01-12.|[2]Reozalimab. IMGT/mAb-DB.

Shipping Conditions

Dry Ice

Storage Conditions

Store at -80°C for 2 years

Scientific Category

Inhibitory Antibodies

Clinical Information

Phase 1

Available Sizes

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

GTR15124488 1 Vial

Lentiviral human ACTR10 shRNA (UAS) - Lentiviral human ACTR10 shRNA (UAS, RFP) (100)

Ask

View Details

TRC-G387585-25MG 25 mg

20(S)-Ginsenoside Rh2

Ask

View Details

NBP3-12074AF594 0.1 mL

Rabbit Monoclonal CD37 Antibody (IPO-24 (ZC37-24)) [Alexa Fluor 594]

Ask

View Details